BHVN vs KROS
BHVN: Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using proprietary protein degradation and ion channel platforms. KROS: Clinical-stage biotech developing TGF-beta-targeting protein therapeutics for rare neuromuscular and hematologic diseases with one Phase 3 program licensed to Takeda.
Side-by-side fundamentals
| Metric | BHVN | KROS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.75 | $10.21 | |
| Market cap as of 2026-07-23 | $2.3B | $202M | |
| P/E as of 2026-07-23 | n/a | 2.32 | |
| PEG as of 2026-07-23 | n/a | -0.00 | |
| Net margin as of 2026-07-23 | n/a | -256.6% | |
| Operating margin as of 2026-07-23 | n/a | -332.6% | |
| ROE as of 2026-07-23 | -450.0% | -17.0% | KROS higher |
| ROA as of 2026-07-23 | -138.0% | -15.8% | KROS higher |
| Debt / equity as of 2026-07-23 | 1.87 | 0.00 | KROS lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -84.5% | |
| Beta as of 2026-07-23 | 2.98 | 1.01 | |
| 1-year return as of 2026-07-22 close | +12.3% | -23.4% | BHVN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.